Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Multicenter, Open-label, and Dose-escalation Study of ACP-196 in Subjects With Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

NCT02029443 is registered in ClinicalTrials.gov with Acerta Pharma BV as lead sponsor.

NCT NCT02029443
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02029443 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Multicenter, Open-label, and Dose-escalation Study of ACP-196 in Subjects With Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
Lead sponsor
Acerta Pharma BV
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
January 30, 2014
Completion date
June 9, 2027
Enrollment
306 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, prolymphocytic leukemia, richter's syndrome, small lymphocytic lymphoma